advances in promoting wakefulness in narcolepsy michael thorpy m.d. montefiore medical center and...
TRANSCRIPT
![Page 1: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/1.jpg)
Advances in Promoting Wakefulness in Narcolepsy
Michael Thorpy M.D.
Montefiore Medical Center
and
the Albert Einstein College of Medicine
Bronx, New York
NESS, Boston, March 27, 2010
![Page 2: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/2.jpg)
Narcolepsy Treatment Goals Reduce excessive sleepiness Control cataplexy
Other associated REM-related symptoms (sleep paralysis, hypnagogic and hypnopompic hallucinations)
Improve nighttime sleep Reduce psychosocial problems
Krahn LE et al. (2001), Mayo Clin Proc 76(2):185-194; Black J (2001), Central Nervous System News Special Edition 25-29; U.S. Xyrem Multicenter Study Group (2002), Sleep 25(1):42-49
![Page 3: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/3.jpg)
Narcolepsy: Management Approaches
Excessive daytime sleepiness Structured nocturnal sleep Naps: scheduled and prn Stimulants or wake-promoting agents Sodium Oxybate
Cataplexy Antidepressants (TCA, SSRI, NERI) Sodium oxybate
Parkes D (1994), Sleep 17(suppl):S93-S96; Mitler MM et al. (1994), Sleep 17(4):352-371; Daly DD, Yoss RE (1976), Narcolepsy. In: Handbook of Clinical Neurology Vol. 15, Vinken PJ, Bruyn GW, eds. New York: Elsevier Publishing, pp836-852; Bassetti C, Aldrich MS (1996), Neurol Clin 14(3):545-571; Mamelak M et al. (1986), Sleep 9(1 pt 2):285-289
![Page 4: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/4.jpg)
Narcolepsy: Management Approaches (Cont.)
Sleep fragmentation Sleep hygiene Hypnotics Sodium oxybate
Sleep disorders Hypnagogic Hallucinations – TCA’s, sodium oxybate Nightmares – TCA’s, sodium oxybate Sleep Paralysis – TCA’s, sodium oxybate Periodic Limb Movements – Dopamine agonists REM Sleep Behavior Disorder – Clonazepam, melatonin
Parkes D (1994), Sleep 17(suppl):S93-S96; Mitler MM et al. (1994), Sleep 17(4):352-371; Daly DD, Yoss RE (1976), Narcolepsy. In: Handbook of Clinical Neurology Vol. 15, Vinken PJ, Bruyn GW, eds. New York: Elsevier Publishing, pp836-852; Bassetti C, Aldrich MS (1996), Neurol Clin 14(3):545-571; Mamelak M et al. (1986), Sleep 9(1 pt 2):285-289
![Page 5: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/5.jpg)
Narcolepsy: Management Approaches (Cont.)
General Personal and family counseling Support –
Narcolepsy Network State funded support programs
Sleep hygiene Naps
![Page 6: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/6.jpg)
Treatment of Excessive Sleepiness
Daytime Sleepiness Stimulants
Methylphenidate Dextroamphetamine Methamphetamine
Modafinil/ Armodafinil Sodium Oxybate
![Page 7: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/7.jpg)
Physicians’ Desk Reference (2005), Montvale, N.J.: Medical Economics Company; Nishino S, Mignot E (2005), Wake-promoting medications: basic mechanisms and pharmacology. In: Principles and Practice of Sleep Medicine, Kryger MH et al., eds. Philadelphia: ElsevierPhysicians’ Desk Reference (2005), Montvale, N.J.: Medical Economics Company; Nishino S, Mignot E (2005), Wake-promoting medications: basic mechanisms and pharmacology. In: Principles and Practice of Sleep Medicine, Kryger MH et al., eds. Philadelphia: Elsevier
Stimulants and Wake-Promoting Medications
C-IV
C-II
C-II
C-II
C-II
Schedule
3-55-60 mg/dayTablets, SR, LAMethylphenidate
15200-400 mg/dayTabletsModafinil
10-135-60 mg/dayCapsules, XRAmphetamine sulfate/saccharate/aspartate (Adderall)
4-55-60 mg/dayTabletsMethamphetamine (Desoxyn)
125-60 mg/dayTablets, SRDextroamphetamine
T1/2
(Hours)DoseFormulationsDrug
C-IV 15150-250 mg/dayTabletsArmodafinil
![Page 8: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/8.jpg)
Alerting Agents
Sympathomimetic: enhance neurotransmission of dopamine, norepinephrine, serotonin
Caffeine: adenosine receptor antagonist Modafinil: specific mechanism remains unclear
Mechanism
![Page 9: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/9.jpg)
Considerations for Use of Stimulants and Wake-Promoting Agents
Drug-drug interactions: CYP 450
Adverse effects: anxiety/nervousness,
restlessness, insomnia, headache, tremor,
dyskinesia, tachycardia, hypertension, psychosis
Abuse potential
Tolerance
![Page 10: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/10.jpg)
Medial Prefrontal Cortex Regions (BA 10) Activated by Caffeine vs. Placebo During Verbal Working Memory
Adapted from Koppelstaetter et al. (2008)
Caffeine
![Page 11: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/11.jpg)
Rx
Adapted from Killgore et al. (2008)
Clock Time
![Page 12: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/12.jpg)
Sites of Action of Amphetamines
Courtesy of Thomas Scammell, MD.
Amphetamine Dopaminereuptake
transporter
VesicularMonoaminetransporter
Dopamine
Dopaminereceptors
MAO
+
![Page 13: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/13.jpg)
High-dose Stimulants
58 patients who were taking high-dose stimulants for narcolepsy or idiopathic hypersomnia were compared with 58 control patients.
High dose stimulants were >120mg/day. The prevalence of psychosis, psychiatric
hospitalizations, tachyarrhythmias, polysubstance abuse, anorexia and weight loss were significantly increased in the stimulant group.
Auger et al. Risks of high dose stimulants in the treatment of disorders of excessive somnolence. A case control study. Sleep 2005;28:667-672
![Page 14: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/14.jpg)
Pharmacotherapy: Sleepiness Modafinil
150 - 500 mg/day Moderate efficacy, long half life Best side effect profile Schedule IV, most expensive
Methylphenidate 5 - 100 mg/day Short half life formulation, variable dosing Used alone or in combination Sympathomimetic effects, mood alterations
![Page 15: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/15.jpg)
Modafinil: Sites of Action Chemically unrelated to CNS stimulants Inhibits the dopamine transporter (DAT)
Contrary to amphetamine, may not induce release of dopamine
Activates wake-promoting neurons Inhibits norepinephrine transporter in the VLPO
Contrary to amphetamine, may not induce release of norepinephrine
Enhanced norepinephrine inhibits sleep promoting VLPO neurons
Stimulates hypocretin release Stimulates histamine release from the TMN
VLPO = Ventrolateral preoptic area
![Page 16: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/16.jpg)
Modafinil: Sites of Action
VLPO = Ventrolateral preoptic area
Tuberomamillary nucleusStimulationHistamine
Lateral hypothalamusStimulationHypocretin
VLPOInhibition of the NE reuptake
transporter
Norepinephrine (NE)
Multiple arousal systemsInhibition of dopamine reuptake
transporter
Dopamine
Site of ActionMethod of actionNeurotransmitter
![Page 17: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/17.jpg)
Proposed Sites of Action of Modafinil
Dopaminereuptake
transporter
Dopamine
Dopaminereceptors
MAO
MAO
Norepinephrinereuptake
transporter
Norepinephrine
Wake-promotingneurons
2 Norepinephrinereceptors
Sleep-promotingneurons
(GABA; VLPO)
Modafinil
+
-
![Page 18: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/18.jpg)
–
Alerting Agents Stabilize Wakefulness
GABA
NorepinephrineHistamine
DopamineSerotonin
Acetylcholine
Wake
GABA(ventrolateral
Preopticarea)
Sleep
–
ModafinilAmphetamines
+
Modafinil
– NorepinephrineSerotonin
![Page 19: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/19.jpg)
Pharmacokinetic Properties of Modafinil
Pharmacokinetics Linear, Independent of dose
Peak Plasma Concentration 2 - 4 hrs, Tmax delayed (~ 1 hr) by food
Plasma Protein Binding: Moderate (~60%)
Elimination Half-life 15 hrs
Metabolism: Metabolized by liver (~90%)
Urinary Excretion: < 10% of unchanged drug, All metabolites
![Page 20: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/20.jpg)
-5.7+2.4+1.9
18.02.75.9
-4.4+1.9+2.1
17.43.06.1
ESSMSLTMWT
Narcolepsy II
-4.1+1.9+2.3
17.13.36.6
-3.5+1.8+2.3
17.92.95.8
ESSMSLTMWT
Narcolepsy I
---
---
-1.5+1.7-2.6
7.32.1
12.5
KSSMSLTPVT
SWD
-4.5+1.5
13.6-4.5+1.6
13.1ESSMWT
OSA II study
-4.6+1.2
14.27.4
--
--
ESSMSLT
OSA I study
Change from
baseline
BaselineChange from
baseline
Baseline
Modafinil 400mgModafinil 200mgMeasuresDisorder
Modafinil
![Page 21: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/21.jpg)
MWT Sleep Latency: Split-Dose vs AM Dosing Regimens
MWT Sleep Latency: Split-Dose vs AM Dosing Regimens
Morning (9-11 AM)
Afternoon (1-3 PM)
Evening (5-7 PM)
Mea
n (
+S
EM
) M
WT
ch
ang
e fr
om
bas
elin
e
0
5
10
15
* †
400 mg split-dose
400 mg qd
200 mg qd
The % of patients able to sustain wakefulness was highest in the morning with the 400-mg single dose and in the evening with the split dose regimen
*P<.001 vs 200 mg qd†P<.05 vs 400 mg qd Schwartz JRL, et al. Clin Neuropharmacol. 2003;26:252-257.
N=32
![Page 22: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/22.jpg)
MWT Sleep Latency: MWT Sleep Latency: Comparing Split-Dose RegimensComparing Split-Dose Regimens
MWT Sleep Latency: MWT Sleep Latency: Comparing Split-Dose RegimensComparing Split-Dose Regimens
Morning (9-11 AM)
Afternoon (1-3 PM)
Evening (5-7 PM)
% o
f p
atie
nts
aw
ake
for
20 m
inu
tes *
* 400 mg split-dose
400 mg qd
200 mg qd
*P<.05 vs 200 or 400 mg qdSchwartz JRL, et al. J Neurol Clin Neurosci. 2004; 27(2): 74-79.
600 mg split-dose
0
50
70
80
40
30
20
10
60
N=24
![Page 23: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/23.jpg)
Armodafinil (Nuvigil)
R-(-)-modafinil
Longer acting isomer of modafinil
Half life approximately 3 x S-(-)-modafinil
![Page 24: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/24.jpg)
Armodafinil
+2.69.5+1.312.1MWTNarcolepsy
--+3.02.3MSLTSWD
--+2.323.7MWTOSA II
+2.223.3+1.721.5MWTOSA I
Change from
baseline
Baseline Change from
Baseline
Baseline
Armodafinil 250mgArmodafinil 150mgMeasuresDisorder
![Page 25: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/25.jpg)
Modafinil / armodafinil
N/A100-400mgnoFatigueEDS
Traumatic Brain Injury
N/A200-400mgnoFatigueChronic fatigue syndrome
N/A100-400mgnoEDSParkinson’s disease
N/A200-400mgnoFatigueMultiple Sclerosis
N/A100-400mgnoFatigueDepression
150 – 250mg200-400mgyesEDSNarcolepsy
150mg200-400mgyesEDSShift Work Disorder
150 – 250mg200-400mgyesEDSObstructive Sleep Apnea
ArmodafinilDoses studied
ModafinilDoses studied
FDA approvalSymptomsDiagnosis
![Page 26: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/26.jpg)
4%6%Diarrhea
not reported3%Hypertension
1%4%Flu syndrome
6%6%Back pain
not reported7%Rhinitis
5%5%Insomnia
4%5%Anxiety
1%7%Nervousness
5%5%Dizziness
7%11%Nausea
17%34%Headache
ArmodafinilModafinilAdverse Effects
Modafinil / Armodafinil
![Page 27: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/27.jpg)
Sodium Oxybate: Physiology Endogenous metabolite of GABA
Affects the GHB and GABA-B receptors
Neuromodulator
GABA
Dopamine
Serotonin
Endogenous opioids
Evidence for role as neurotransmitter
Synthesized in neurons, stored in vesicles, released via depolarization into synaptic cleft, reuptake, specific receptors
![Page 28: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/28.jpg)
Sodium Oxybate: Pharmacokinetics
Absorption Tmax = 0.5 h-1.25 h
Dose proportionality Nonlinear kinetics
Distribution <1% protein bound
Metabolism Bioavailability ~25% (hepatic first-pass metabolism)
Diffuse cellular metabolismEnd product CO2 + H2O
No active metabolite
Elimination Predominantly metabolized
~5% unchanged in urine
T1/2 = 40-60 min
Food Slows bioavailability (AUC 30% with full meal)
AUC = area under the curve.
![Page 29: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/29.jpg)
Sodium Oxybate: Sites of Action
GABA
Sodium Oxybate
H2N
OH
O
NaOOH
O
GABA-AGABA-B GHB receptor
-O
OH
O
Na+
![Page 30: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/30.jpg)
Sodium Oxybate: CNS Pharmacology
Binds to GABAB receptor Antagonism and deletion of GABAB in animal
models inhibits sodium oxybate–induced sleep and some neuromodulation effects
Dual effect on noradrenergic locus coeruleus Inhibition during administration of sodium
oxybate Potentiation following cessation of treatment
![Page 31: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/31.jpg)
Sodium Oxybate - Modafinil: 8-Week, Double Blind, Placebo-Controlled Trial Treatment Arms
N=222. SXB-22 .
*Placebo: sodium oxybate; †Placebos: modafinil + sodium oxybate; §Placebo: modafinil.
Data on file, Orphan Medical.
Sodium oxybate§6.0 g 9.0 g
n=50
200 to 600 mg/day
Modafinil*(unchanged dosing)
n=63
200 to 600 mg/day200 to 600 mg/day
Modafinil(single blinded *)
Placebo† (modafinil withdrawn)
n=55
200 to 600 mg/day
Week
6.0 g 9.0 gModafinilSodium oxybate
-4 0 4 8
n=54200 to 600 mg/day200 to 600 mg/day
Baseline Endpoint
![Page 32: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/32.jpg)
N=230. SXB-22. MWT = Maintenance of Wakefulness Test.Data on file, Orphan Medical.
0
1
2
3
4
5
6
7
Placebo(modafinil withdrawn)
Modafinil Sodium oxybate
Modafinil +sodium oxybate
Dif
fere
nc
e o
f th
e m
ea
ns
(m
in)
Difference from placebo (modafinil withdrawn)
P<0.001
P=0.002
P<0.001
Sodium Oxybate - Modafinil: 8-Week, Placebo-Controlled Trial MWT Sleep Latency
![Page 33: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/33.jpg)
Treatment SuggestionsMain Symptom: Severe or moderate daytime sleepiness: Modafinil
Moderate or mild sleepiness, and disturbed nocturnal sleep: Sodium oxybate
Severe sleepiness and severe cataplexy: Sodium oxybate and modafinil
Mild sleepiness and cataplexy: Sodium oxybate
Nocturnal sleep symptoms: Fragmented sleep, hypnagogic hallucinations and nightmares: Sodium oxybate
![Page 34: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/34.jpg)
Agents Under Development Non-hypocretin-based therapies
Histaminergic H3 antagonist/inverse agonists Novel monoaminergic reuptake inhibitors Novel SWS enhancers TRH analogues
Hypocretin-based Therapy Hypocretin-1 Hypocretin peptide agonist Nonpeptide agonist Hypocretin cell transplantation Gene therapy
Immune-based therapies Steroids IVIg Plasmapheresis
![Page 35: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/35.jpg)
** p<0.01 ANOVA with post-hoc, vs. N. Controls
Histamine in Sleep Disorders
0 400 600 800 10002 0 0
CSF histamine levels (pg / ml)
**
**
**
**
(B2) Hcrt-/N/C/med+
(B1) Hcrt-/N/C/med-
(C) Hcrt+/N/C/med-
(D1) Hcrt-/N/woC/med-
(D2) Hcrt-/N/woC/med+
(E) Hcrt+/N/woC/med-
(F1) IHS/med-
(F2) IHS/med+
(G) OSAS
(A) Neurological controls
Kanbayashi T, Kodama T, Kondo H, Satoh S, Inoue Y, Chiba S, Shimizu T, Nishino S. CSF histamine contents in narcolepsy, idiopathic hypersomnia and obstructive sleep apnea syndrome. Sleep. 2009 Feb 1;32(2):181-7.
![Page 36: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/36.jpg)
Histamine and Sleep Histamine neurons project to practically all brain regions, including areas
important for vigilance control, such as the hypothalamus, basal forebrain, thalamus, cortex, and brainstem structures.
Hcrtr 1 is enriched in the ventromedial hypothalamic nucleus, tenia tecta, hippocampal formation, dorsal raphe, and locus coeruleus (LC).
Hcrtr 2 is enriched in the paraventricular nucleus, cerebral cortex, nucleus accumbens, ventral tegmental area, substantia nigra, and histaminergic TMN.
TMN exclusively expresses Hcrtr 2.
Hypocretin potently excites TMN histaminergic neurons through Hcrtr 2. Wake-promoting effects of hypocretins are totally abolished in histamine
H1 receptor KO mice, Therefore, the wake-promoting effects of hypocretin is dependent on the
histaminergic neurotransmission 1
1. Barbier AJ, Bradbury MJ. Histaminergic control of sleep-wake cycles: recent therapeutic advances for sleep and wake disorders. CNS Neurol Disord Drug Targets 2007;6:31-43.
![Page 37: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/37.jpg)
Histamine Receptor Subtypes There are four histamine receptor subtypes, (H1R-H4R) All G protein coupled receptors (GPCRs). Greater than 50% of
the most successful pharmaceutical treatments are drugs that act via GPCRs pathways.
H1R blockers have sedative effects are anti-allergy. H2R based drugs are anti-ulcer drugs. H3R antagonists activate histaminergic neurons, increasing
histamine, and producing wakefulness. H4R is expressed in hematopoietic cells suggesting a strong
role in inflammatory and immunomodulatory processes.
![Page 38: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/38.jpg)
Histaminergic H3R Antagonists H3R, presynaptic autoreceptor of histamine neurons.
Histamine inhibits its own synthesis and release by a negative feedback process and that these actions are mediated by H3 receptors.
Stimulation of H3R causes sedation, antagonism causes wakefulness.
H3R is densely located centrally in the hippocampus, amygdala, nucleus accumbens, globus pallidus, hypothalamus striatum, substantia nigra, and the cerebral cortex.
Peripherally, H3R are also located in the GI tract, airways and cardiovascular system.
H3R antagonists are being studied for sleep wake disorders, ADHD, epilepsy, cognitive impairment, schizophrenia, obesity, and neuropathic pain.
![Page 39: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/39.jpg)
Histamine 3 receptor (H3R) antagonists
Effective in canines on sleepiness and cataplexy Promotes wakefulness in mice with ablation of hypocretin
neurons (ataxin-3)
H3R antagonists thioperamide, carboperamide, and ciproxifan have been tested in rats, mice and cats.
Increase in wakefulness without rebound hypersomnolence or increasing locomotor activity.
APD916 is currently in Phase 1 trials for narcolepsy by Arena Pharmaceuticals
1. Barbier AJ, Bradbury MJ. Histaminergic control of sleep-wake cycles: recent therapeutic advances for sleep and wake disorders. CNS Neurol Disord Drug Targets 2007;6:31-43.
![Page 40: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/40.jpg)
Histaminergic H3R Inverse Agonists- Tiprolisant
Tiprolisant or BF2.649 is the first H3 inverse agonist that passed clinical Phase II trials in the treatment of EDS in narcolepsy.
In a pilot study single blinded with 22 patients, receiving a placebo followed by tiprolisant for one week, the ESS was reduced from baseline of 17.6, by 5.9 with tiprolisant compared to 1.0 for placebo.
Effect similar to modafinil.
Tiprolisant has been granted orphan drug status by the European Medicine Agency for the therapeutic treatment of narcolepsy.
Multiple other compounds in development: Conessine , JNJ-637940 , GSK 189254
Lin JS, Dauvilliers Y, Arnulf I, et al. An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-/- mice and patients. Neurobiol Dis 2008;30:74-83.
![Page 41: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/41.jpg)
Hypocretin
Intracerebroventricular hypocretin replacement, intranasal hypocretin administration, hypocretin cell transplantation, hypocretin gene therapy, and hypocretin stem cell transplantation are being studied for narcolepsy.
Hypocretin-1 low permeability to the blood-brain barrier. Hypocretin-2 does not cross the blood-brain barrier. Hypocretin-1 more stable in the blood and CSF than
hypocretin-2. Hypocretin-1 binds with two to three times the affinity to
HCTR-1 than hypocretin-2
![Page 42: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/42.jpg)
Systemic and ICV Hypocretin-1
Intra-cerebro-ventricular (ICV) hypocretin-1 can suppress cataplexy and improve sleep in narcoleptic mice and canines.
Not effective in hcrt2 mutated dogs.
Systemic administration of hypocretin-1 in canines with narcolepsy produces increases in activity levels, wake times, reduces sleep fragmentation, and has a dose dependent reduction in cataplexy.
Small peptide hypocretin analogues might be an alternative.
Intranasal hypocretin administration holds promise.
![Page 43: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/43.jpg)
Intranasal Hypocretin-1
Intranasal hypocretin bypasses the blood brain barrier with the added benefits of onset of action within minutes and fewer peripheral side effects.
Intranasal delivery works through the olfactory and trigeminal nerves.
The mechanism of action is extracellular so there is no dependence on receptors or axonal transport for drug delivery.
Csf fluid levels are detectable after intranasal delivery of hypocretin. Intranasal hypocretin concentrations were highest in the
hypothalamus and the trigeminal nerve.
Hanson LR , Taheri M, Kamsheh L, et al. Intranasal administration of hypocretin 1 (orexin A) bypasses the blood-brain barrier and target the brain: a new strategy for the treatment of narcolepsy. . Drug Deliv Tech 2004;4:1-10.
Born J, Lange T, Kern W, et al.. Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci 2002;5:514-6.
![Page 44: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/44.jpg)
Hypocretin Gene Therapy
Aimed at stimulating the production of hypocretin. Ectopic transgenic expression of hypocretin in mice
prevents cataplexy even with hypocretin neuron ablation.
Hypocretin gene therapy with viral vectors are a potential future treatment for narcolepsy-cataplexy.
Mieda M, Willie JT, Hara J, et al. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc Natl Acad Sci U S A 2004;101:4649-54.
![Page 45: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/45.jpg)
Hypocretin Cell Transplantation
Normal subjects have approximately 70,000 hypocretin neurons and in narcolepsy-cataplexy, 85-95% of hypocretin neurons are lost.
A minimum of 10% of hypocretin producing cells need to be replaced for a therapeutic effect.
Transplantation is limited by graft survival and immune reactions. Transplantation of neonatal rat hypothalami into the brainstem of
adult rats produced poor graft survival. Donor supply may be a problem if the survival of grafts is
improved.
The barrier of graft survivability, graft reactions, and cost barriers could be reduced if genetically engineered cells or employing stem cell techniques were used instead.
![Page 46: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/46.jpg)
Thyrotrophin-releasing Hormone Agonists
TRH is a small peptide of 3 amino acids
TRH receptor-1 is found predominantly in the hypothalamus. TRH receptor-2 is more widespread and in the reticular nucleus of
the thalamus.
TRH in high dose stimulates wakefulness and anticataplectic in the narcoleptic canine
TRH is excitatory on neurons and enhances dopamine and adrenergic transmission.
May promote wakefulness by direct effect on thalamocortical pathways
Nishino S, Arrigoni J, Shelton J, et al. Effects of thyrotropin-releasing hormone and its analogs on daytime sleepiness and cataplexy in canine narcolepsy. J Neurosci 1997;17:6401-8
![Page 47: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/47.jpg)
Thyrotrophin-releasing hormone agonists
Three compounds had a significant impact on cataplexy, whereas only two of the three had benefit in excessive sleepiness.
Oral CG-3703 at two weeks was shown to reduced cataplexy and excessive sleepiness in a dose dependent manner. The effective dose in producing wakefulness was similar to a
reasonable dose of D-amphetamine. The action CG-3703 is due to enhancement of dopaminergic
effects.
TRH-degrading enzyme inhibitor, metallopeptidase, may be promising.
Nishino S, Arrigoni J, Shelton J, et al. Effects of thyrotropin-releasing hormone and its analogs on daytime sleepiness and cataplexy in canine narcolepsy. J Neurosci 1997;17:6401-8
![Page 48: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/48.jpg)
Immune-based Therapies
Steroids: Ineffective in 1 human and 1 canine case
Plasmapheresis Little data available More invasive than IVIg
IVIg Effective in two studies
May need to be used early (<1 year of onset) No placebo controlled trials Generally safe but can cause life threatening side effects.
![Page 49: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/49.jpg)
Intravenous Immunoglobulin (IVIg)
One case study 10 year old (Lecendreaux et al.) Sleepiness and cataplexy improved.
4 case studies (Dauvilliers et al.) Cataplexy improved.
4 cases (Zuberi et al.) Sleepiness improved more than cataplexy.
Lecendreux M, Maret S, Bassetti C, Mouren MC, Tafti M. Clinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boy. J Sleep Res. 2003 Dec;12(4):347-8.
Yves Dauvilliers MD, Bertrand Carlander MD, François Rivier MD, PhD, Jacques Touchon MD, Mehdi Tafti, PhD. Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset Ann Neurol. 2004 Dec;56(6):905-8.
Zuberi SM, Mignot E, Ling L, McArthur I. Variable response to intravenous immunoglobulin therapy in childhood narcolepsy. J Sleep Res., 2004;13(suppl1) 828.
![Page 50: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/50.jpg)
Future Directions
Other potential targets for reducing EDS will likely involve: Developing novel neuropeptides Targeting:
proteins such as circadian clock proteins,
specific ion channels such as prokineticin or neuropeptide S.
![Page 51: Advances in Promoting Wakefulness in Narcolepsy Michael Thorpy M.D. Montefiore Medical Center and the Albert Einstein College of Medicine Bronx, New York](https://reader036.vdocuments.mx/reader036/viewer/2022062409/56649e4b5503460f94b3fa72/html5/thumbnails/51.jpg)
Conclusion
Pharmacological treatment of Narcolepsy involves not only treatment of Daytime Sleepiness and Cataplexy, but also Nocturnal Sleep.
Current treatment involves the use of Modafinil, Stimulants, Sodium Oxybate, adrenergic/serotonergic inhibitors.
New experimental treatment options for early onset narcolepsy include immune suppression treatments.
Future treatments may target hypocretin and histaminergic systems.